Skip to main content
. Author manuscript; available in PMC: 2020 May 8.
Published in final edited form as: Integr Biol (Camb). 2019 Nov 26;11(7):301–314. doi: 10.1093/intbio/zyz025

Figure 4.

Figure 4.

ATI450 treatment inhibits pro-inflammatory signaling.(a and b) Luminex analysis of cytokine abundance in distal colon tissue from control and inflamed mice treated with or without ATI450 for 2 weeks. Data are concentration Z-scores of all analytes (a) or concentration of G-CSF, MIP2, IP-10, or MIP-1α (b) with 7 mice/group (three technical replicates per mouse, averaged). (c and d) Luminex analysis of phosphoproteins in lysates of distal colon tissue from control and inflamed mice treated with or without ATI450 for 2 weeks.Data are raw fluorescence (RFU) Z-scores of all analytes (c) or relative amount of AKT (Ser473) and ATF-2 (Thr71) (d) with 7 mice/group (three technical replicates per mouse, averaged). Error bars shown as mean ± SEM. ∗p < 0.05, ∗∗p < 0.01, and ∗∗∗p < 0.005 by Wilcoxon Rank Sum test.